Table 2.
INASL Guidance for Treatment of Chronic Hepatitis C.
| Genotype | Scenario | Treatment regimen |
|---|---|---|
| 1 | Recommended regimen for genotype 1a or 1b | • SOF (400 mg) + LDV (90 mg) × 12 weeks • SOF (400 mg) + DCV (60 mg) × 12 weeks |
| For patients with cirrhosis | • SOF (400 mg) + LDV (90 mg) × 24 weeks • SOF (400 mg) + LDV (90 mg) + weight-based RBVa for 12 weeks • SOF (400 mg) + DCV (60 mg) × 24 weeks • SOF (400 mg) + DCV (60 mg) + weight-based RBVa for 12 weeks |
|
| 2 | Recommended regimen | • SOF (400 mg) + weight-based RBV × 12 weeks |
| Alternative regimen for RBV-intolerant patients | • SOF (400 mg) + DCV (60 mg) × 12 weeks | |
| For patients with cirrhosis | • Increase treatment duration to 16 weeks | |
| Alternative regimen in cirrhotics | • SOF (400 mg) + DCV (60 mg) × 12 weeks | |
| 3 | Recommended regimen | • SOF (400 mg) + DCV (60 mg) × 12 weeks • SOF (400 mg) + weight baseda RBV × 24 weeks |
| For patients with cirrhosis | • SOF (400 mg) + DCV (60 mg) + weight baseda RBV × 24 weeks | |
| Alternative regimen in compensated cirrhotics | • SOF (400 mg) + Peg-IFNα weekly + weight baseda RBV × 12 weeks | |
| 4 | Recommended regimen | • SOF (400 mg) + LDV (90 mg) × 12 weeks |
| Alternative regimen | • SOF (400 mg) + Peg-IFNα weekly + weight baseda RBV × 12 weeks • SOF (400 mg) + weight baseda RBV × 24 weeks |
|
| For patients with cirrhosis | • SOF (400 mg) + LDV (90 mg) × 24 weeks • SOF (400 mg) + LDV (90 mg) + weight-based RBVa for 12 weeks |
|
| 5 & 6 | Recommended regimen | • SOF (400 mg) + LDV (90 mg) × 12 weeks |
| Alternative regimen | • SOF (400 mg) + Peg-IFNα weekly + weight based RBVa × 12 weeks | |
| For patients with cirrhosis | • SOF (400 mg) + LDV (90 mg) × 24 weeks • SOF (400 mg) + LDV (90 mg) + weight-based RBVa for 12 weeks |
DCV, daclatasvir; LDV, ledipasvir; Peg-IFNα, pegylated interferonα; RBV, ribavirin; SOF, sofosbuvir.
a
Weight-based RBV (1000 mg if weight <75 kg and 1200 mg if >75 kg, as tolerated).